Search Results
You are looking at 1 - 10 of 10 items for
- Author or Editor: Kenar Jhaveri x
- Refine by Content Type: All x
The knowledge and understanding of hypertension (HTN) have always been cornerstones of nephrology, and over the last 3 decades, nephrologists have emerged at the forefront of HTN management. As we look back over the last few years, several major trials and findings have emerged, leading to some changes in our ways of thinking and practice. I’ll highlight the top 10 major findings and studies that are making an impact in HTN management. In 2022, we need to continue to take ownership of HTN as nephrologists.
The past decade has seen continual progress in the diagnosis and treatment of primary glomerular diseases. The discovery of disease-causing autoantibodies in membranous nephropathy (MN) and mutations in podocyte genes in focal segmental glomerulosclerosis (FSGS), together with the availability of modern immunosuppressive drugs, has provided new avenues for individualized therapy, and several important studies have been published in the past several years.
Whereas antibodies to the phospholipase A2 receptor (PLA2R) were discovered over 10 years ago and have entered mainstream practice, several novel antigens surfaced in the nephrology literature in 2020 (
Detective Nephron, world-renowned for his expert analytic skills, trains budding physician-detectives, most recently L.O. Henle, in the diagnosis and treatment of kidney diseases. Mackenzie Ula Densa, a budding nephrologist, plans to present a new case to the master consultant.
Detective Nephron, world-renowned for expert analytic skills, trains budding physician-detectives on the diagnosis and treatment of kidney diseases. Mackenzie Ula Densa, a budding nephrologist, plans to present a new case to the master consultant.
Drug discovery and development is a lengthy and expensive process. Testing new agents in humans at an early stage can reduce the time and costs involved in identifying drugs that are likely to succeed in clinical studies. Implementation of a new drug in practice also requires the development of useful biomarkers of disease and of the drug’s efficacy, as well as sensitive molecular imaging techniques.
Nephrology relied on only a handful of therapeutics during the 1970s to 2000s for managing anemia, bone-mineral disease, glomerular diseases, and transplantation-related events. In the past 2 decades, there has been a steady rise in
Detective Nephron, world renowned for expert analytic skills, trains budding physician-detectives on the diagnosis and treatment of kidney diseases. Wildly waving a stack of paper records, budding nephrologist L.O. Henle and medical student Ms. Curious Tubule run down the hall toward Detective Nephron’s office.
Henle (
Nephron (
Henle It’s a case of metabolic acidosis.
Nephron (
Traditionally, the field of hematology-oncology has elicited a feeling of despair and morbidity in many until a few years ago. However, with the growing advances in the field of oncology, there are a larger number of patients who are being diagnosed with cancers and an even larger number surviving cancer. With this change in the field of oncology, we—as nephrologists—encounter many patients who develop kidney diseases due to cancer or the therapy used for the treatment of cancer.
From electrolyte and acid-base imbalance to acute and chronic kidney disease, including glomerular diseases, nephrologists are seeing a growing number of patients
Lupus nephritis is a serious end organ manifestation of systemic lupus erythematosus (SLE). Regardless of the remarkable advances in the knowledge and understanding of lupus nephritis pathophysiology, it remains a weighty source of morbidity and mortality, and 10% to 30% of affected patients progress to end-stage kidney disease within 10 years of being diagnosed with SLE (
Therapy for lupus nephritis has continued to evolve, from the use of cyclophosphamide, azathioprine, and steroids developed in the 1970s–1980s to the use of mycophenolate, tacrolimus, cyclosporine, and rituximab in the 2000s (
In 1914, Volhard and Fahr (
The outlook for securing a job after nephrology training has become increasingly more difficult. A glance at the
The survey was created online using
